Zevra Therapeutics (ZVRA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: SVP of $ZVRA Sells 3,000 Shares
Quiver QuantitativeFeb 14 18:01 ET
Zevra Therapeutics Insider Sold Shares Worth $727,390, According to a Recent SEC Filing
MT NewswiresFeb 14 17:56 ET
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $21
Moomoo NewsFeb 10 09:31 ET · Ratings
Guggenheim Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $21
Moomoo NewsFeb 4 03:32 ET · Ratings
Zevra Therapeutics' MIPLYFFA Receives 2025 New Treatment Award at WORLDSymposium; Eight Abstracts Accepted for Presentation
Quiver QuantitativeJan 30 07:42 ET
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium
GlobeNewswireJan 30 07:30 ET

Comments

Trytosaveabit

Nov 21, 2024 16:02

Update

$Zevra Therapeutics (ZVRA.US)$ Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
GlobeNewswire· 7 mins ago
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense
AmplifyAssist, Zevra's comprehensive patient support program, in place to address access barriers

Jaguar8

Nov 21, 2024 15:57

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectat...

3

Stock_Drift

Nov 11, 2024 15:42

$Zevra Therapeutics (ZVRA.US)$

Jaguar8

Nov 11, 2024 15:37

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
Zevra Therapeutics (NASDAQ: ZVRA) announced the presentation of data validating the swallow domain's significance in the Niemann-Pick Disease Type C Clinical Severity Scale(NPCCSS) at the 53rd Child Neurology Society Annual Meeting. The study, presented by Dr. Elizabeth Berry-Kravis, in...

2

Meltyy

Sep 25, 2024 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

9

1

ZVRA Zevra Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks